Response rates for hip, femoral neck, and lumbar spine bone mineral density in patients treated with abaloparatide followed by alendronate: Results from phase 3 ACTIVExtend
| العنوان: | Response rates for hip, femoral neck, and lumbar spine bone mineral density in patients treated with abaloparatide followed by alendronate: Results from phase 3 ACTIVExtend |
|---|---|
| المؤلفون: | Yamei Wang, Paul D. Miller, Bruce H. Mitlak, Chad L. Deal, Lorraine A. Fitzpatrick |
| المصدر: | Bone Reports Bone Reports, Vol 11, Iss, Pp-(2019) |
| بيانات النشر: | Elsevier, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | musculoskeletal diseases, 0301 basic medicine, ACTIVExtend, ACTIVE extension study, medicine.medical_specialty, lcsh:Diseases of the musculoskeletal system, Endocrinology, Diabetes and Metabolism, Abaloparatide, Osteoporosis, BMD, bone mineral density, Urology, Parathyroid hormone, Bone density conservation agents, 030209 endocrinology & metabolism, Placebo, ITT, intent-to-treat, Article, PTH1R, parathyroid hormone 1 receptor, 03 medical and health sciences, 0302 clinical medicine, medicine, ACTIVE, Abaloparatide Comparator Trial in Vertebral Endpoints, Orthopedics and Sports Medicine, PTH1, parathyroid hormone 1, Bone regeneration, Femoral neck, Bone mineral, Alendronate, business.industry, medicine.disease, medicine.anatomical_structure, Lumbar spine, Postmenopausal, 030101 anatomy & morphology, lcsh:RC925-935, business |
| الوصف: | Highlights • A significantly greater proportion of abaloparatide/alendronate patients had BMD increases over 0, 3 and 6 percent versus placebo/alendronate. • BMD responses were higher at all anatomic sites and for all thresholds assessed for abaloparatide/alendronate versus placebo/alendronate • This study provides further evidence of cumulative benefit from sequential treatment with an anabolic agent followed by an antiresorptive. Abaloparatide is a selective activator of the parathyroid hormone type 1 receptor signaling pathway that favors the stimulation of bone formation. Here, we report a prospective, exploratory analysis of bone mineral density (BMD) response rates comparing sequential abaloparatide/alendronate vs placebo/alendronate across the ACTIVE and ACTIVExtend studies. BMD was measured at the lumbar spine, total hip, and femoral neck from the beginning of ACTIVE to the end of ACTIVExtend (18 months of abaloparatide or placebo followed by about 1 month for re-consent, followed by 24 months of alendronate treatment for a total of 43 months). Responders were defined as those patients who had improvements in BMD at 3 anatomic sites—the lumbar spine, total hip, and femoral neck. Three response thresholds, >0%, >3%, and >6%, were evaluated. Five hundred fifty-eight patients in the abaloparatide/alendronate group and 581 patients in the placebo/alendronate group from ACTIVExtend were included in the analysis. At Month 43, a significantly greater proportion of those in the abaloparatide/alendronate group compared with the placebo/alendronate group responded with BMD changes from ACTIVE baseline of >0%, >3%, and >6% at all 3 anatomic sites (p 3% threshold, 60.7% (307/506) vs 24.0% (121/505) of patients experienced BMD increases at all 3 sites in the abaloparatide/alendronate vs placebo/alendronate groups, respectively (p 0%, >3%, and >6% at each individual anatomic site compared with the placebo/alendronate group at 43 months (p |
| اللغة: | English |
| تدمد: | 2352-1872 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5a68b4ce7297e75843717b1c79f322fTest http://europepmc.org/articles/PMC6883300Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....e5a68b4ce7297e75843717b1c79f322f |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 23521872 |
|---|